Another promising therapeutic strategy for LHON includes gene therapy based on the allotopic expression of the wild-type ND4 subunit in the nucleus, which was evaluated in clinical trials only for patients carrying the m.11778G > A/MT-ND4 mutation but it is not yet approved. This evidence concerns the gene MT-ND4 and Leber hereditary optic neuropathy.